Sign in: Staff/Students
Efforts to develop novel antibiotics are hampered by a number of scientific and regulatory hurdles that cannot be easily tackled by any individual organisation
The University of Liverpool and the Royal Liverpool University Hospital are part of a large European and pharmaceutical partnership to develop new antibiotic treatments.
The Combatting Bacterial Resistance in Europe – Molecules Against Gram-Negative Infections (COMBACTE-MAGNET), project is part of the Innovative Medicines Initiative (IMI), bringing together 33 European academic partners and five pharmaceuticals in research activities to prevent and treat infections that have become resistant to antibiotics.
Antimicrobial resistance (AMR) is a growing problem worldwide, and with few new drugs making it to the market, there is an urgent need for new medicines to manage infections caused by resistant pathogens. Most problematic is the rapid emergence and dissemination of multidrug resistant (MDR) bacteria.
Efforts to develop novel antibiotics are hampered by a number of scientific and regulatory hurdles that cannot be easily tackled by any individual organisation working alone.
The Liverpool team will conduct the first-in-human clinical trials and identify the optimal dosage for patients with life threatening infection for which there are currently severely limited treatment options.
Professor William Hope, from the University’s Institute of Translational Medicine, said: “We have developed the necessary infrastructure and skills that are required for the accelerated development of new antibiotics with activity against drug resistant bacteria.
“The IMI award builds on an existing research theme within the Department of Molecular and Clinical Pharmacology for the development of new drugs for bad bugs.”
Richard Fitzgerald, consultant physician at the Royal Liverpool University Hospital, said: “We are uniquely placed to work together to deliver this important project. The combination of the Clinical Research Unit at the Royal Liverpool and the Antimicrobial Pharmacodynamics & Therapeutics Laboratory at the University means that Liverpool can directly contribute to the development of new drugs that are urgently required for the NHS.”
The COMBACTE-MAGNET project will develop new treatment options for patients with life-threatening infections due to bacterial infections that are resistant to current antibiotics.
You must be logged in to post a comment.
All recent news
COMET Initiative shortlisted for MRC Impact Prize
Report identifies gaps in ethnicity research in maternal care
English Language Centre: Supporting international students on campus
University retains ‘2:1 Class’ sustainability ranking in People & Planet University League
Help us improve our social media to win £50 Everyman Cinema vouchers
Congratulations to @prw_paula and the @COMETinitiative team who have been shortlisted for the #MRCImpactPrize for Open Science Impact! Read the full story ➡️http://bit.ly/3HgWq0M
We were delighted to present ten esteemed figures with honorary degrees in a special ceremony @liverpoolphil yesterday including former MP @LouiseEllman, @Everton CEO Denise Barrett-Baxendale and @TheLegItPodcast host @AndyGbootneck.
Read more here 👉https://news.liverpool.ac.uk/2022/12/06/everton-ceo-and-former-mp-receive-honorary-degrees-from-university-of-liverpool/
An off-patent liver disease drug could prevent #COVID19 infection, a new @Nature study has found.
@livuniHLS scientists played a key role in the collaborative study, which involved a unique mix of ‘mini-organs’, donor organs, animal studies & patients.